| 4.41 Data as of May 17 |  +0.01 / +0.23%Today’s Change | 4.24 Today|||52-Week Range 14.01 | -38.58% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Medical Specialties | MARKET CAP $244.9M |
Company Description
OraSure Technologies, Inc. is engaged in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies, as well as other diagnostic products. It operates through two segments: OraSure and DNAG. OraSure segment consists of development, manufacture and sale of oral fluid diagnostic products and specimen collection devices and the manufacture and sale of medical devices used for the removal of benign skin lesions by cryosurgery. DNAG segment is newly acquired subsidiary of the company, which is based in Ottawa, Canada and manufactures and sells oral fluid collection devices that are used to collect samples of genetic material for molecular testing. OraSure Technologies was founded in May 2000 in and is headquartered in Bethlehem, PA.
Employees
Shareholders
| Individual stakeholders | 9.08% |
| Mutual fund holders | 41.57% |
| Other institutional | 38.16% |
Top Executives
| Douglas A. Michels, MBA | President, Chief Executive Officer & Director |
| Ronald H. Spair, MBA, CPA | COO, CFO, Director & Head-Investor Relations |
| Stephen R. Lee, PhD | Chief Scientific Officer & Executive VP |
| P. Michael Formica, MBA | Executive Vice President & GM-Cryosurgery |
| Jack E. Jerrett | Secretary, Senior Vice President & General Counsel |
.
